MOR103 Presentation - MorphoSys

ePAPER READ

DOWNLOAD ePAPER

morphosys

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

START NOW

ACR-Subcomponent Analysis ESR [mm/hour]

Median Changes from Baseline

Median change from

baseline

treatment period

ACR/ARHP 2012 – Washington DC – November 10-14, 2012

Visit (week)

Download the Corporate Factsheet (PDF) - MorphoSys

Consolidated Financial Statements (IFRS) 2011 - MorphoSys

Company Presentation - J.P. Morgan Healthcare ... - MorphoSys

Thank you Claudia, also from me, a warm welcome to ... - MorphoSys

MorphoSys Issued US Patent for HuCALÃ‚Â® Antibody Library

MORPHOSYS AG AND BAYER SIGN AGREEMENT TO APPLY ...

Transcript of Speech and Q&A Conference Call Q2 - MorphoSys

Invitation to the Annual General Meeting 2012 - MorphoSys

Antibody Engineering Conference, San Diego - MorphoSys

Study Design Streptococcal Cell Wall Induced Arthritis - MorphoSys

ACR-Subcomponent Analysis ESR [mm/hour] Median Changes from Baseline Median change from baseline treatment period ACR/ARHP 2012 – Washington DC – November 10-14, 2012 Visit (week)

DAS28 Response to Treatment MOR103 vs Placebo at Day 29 and 57 ACR/ARHP 2012 – Washington DC – November 10-14, 2012

Page 1 and 2: Abstract-Number: L11 First in Patie
Page 3 and 4: Disclosures • F. Behrens, M. Oste
Page 5 and 6: Anti-GM-CSF Monoclonal Antibody (MO
Page 7 and 8: Study design 0.3 mg/kg MOR103 (n=25
Page 9 and 10: Baseline Disease Characteristics Ch
Page 11 and 12: Patient Disposition Placebo (n=27)
Page 13 and 14: ACR Response at Week 4 Percentage o
Page 15 and 16: EULAR Response at Week 4 Percentage
Page 17 and 18: Change of Synovitis by MRI Analysis
Page 19 and 20: Acknowledgements Investigators �
Page 21: Geographic Distribution of Patients

MOR103 Presentation - MorphoSys

Create successful ePaper yourself

Delete template?

Save as template?